-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China (Zhejiang) Pilot Free Trade Zone Hangzhou Area Xiaoshan Block Construction Plan: The People's Government of Xiaoshan District, Hangzhou officially released the "China (Zhejiang) Pilot Free Trade Zone Hangzhou Area Xiaoshan Block Construction Plan" on its official website, clearly proposing to explore biomedicine Try first, focus on opening up the clinical and commercial approval authority for cell therapy and gene therapy, and explore the establishment of a green channel in the process of application and testing of cell and gene therapy drugs.
Hangzhou Xiaoshan District People's Government Network
The second batch of military hospital stem cell clinical research institutions filed list publicity: The Health Bureau of the Central Military Commission’s Logistics Support Department publicized the second batch of military hospital stem cell clinical research institutions filed list, including the Second Affiliated Hospital of the Army Military Medical University, the Army Characteristic Medical Center, and the Navy Military Medical The Second Affiliated Hospital of the University, the Third Affiliated Hospital of the Naval Military Medical University, the Second Affiliated Hospital of the Air Force Military Medical University, the Third Affiliated Hospital of the Air Force Military Medical University, the Eastern Theater General Hospital, the Central Theater General Hospital, the 920th Hospital, and the 940th Hospital.
Health Bureau of the Logistics Support Department of the Central Military Commission
The world’s first BCMA CAR-T therapy was approved for marketing: Bristol-Myers Squibb and its partner Bluebird Bio recently announced that the U.
Bio Valley
Gilead’s CAR-T therapy Tecartus applies for new indications in the United States: Gilead’s Kite company recently announced that it has submitted a supplementary biological product licensing application (sBLA) for Tecartus to the US Food and Drug Administration, which is a target Chimeric antigen receptor T cell therapy to CD19 is used to treat adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
Bio Valley
Japan approves the listing of CAR-T therapy Breyanzi: Bristol-Myers Squibb recently announced that the Ministry of Health, Labour and Welfare (MHLW) of Japan has approved Breyanzi (lisocabtagene maraleucel, liso-cel), a CD19-oriented, chimeric antigen receptor (CAR) T cell therapy is used to treat: (1) patients with relapsed or refractory large B-cell lymphoma (R/R LBCL); (2) patients with relapsed or refractory follicular lymphoma (R/R FL).
BMS
Mesenchymal stem cells combined with immune cells to treat brain injury: Research published in the journal Science Translational Medicine shows that mesenchymal stem cells (MSC) combined with regulatory T cells (Treg) can play a more important role in the treatment of traumatic brain injury.
Stem cells J
New progress in stem cell treatment of diabetic foot: The results of a phase I clinical trial published in "Stem Cells Translational Medicine" show that a new stem cell therapy is expected to make diabetes-related amputations a thing of the past.
Biology
